Category: quinoxaline

The evaluation of short- and long-term stability studies for brimonidine in aqueous humor by DPV/BDDE method-possible application for direct assay in native samples was written by Radulovic, Valentina;Aleksic, Mara;Kapetanovic, Vera;Rajic, Katarina Karljikovic;Jovanovic, Milos;Marjanovic, Ivan;Stojkovic, Milenko;Agbaba, Danica. And the article was included in Analytical and Bioanalytical Chemistry in 2019.Related Products of 70359-46-5 This article mentions the following:

A novel voltammetric method was developed for brimonidine (BRIM) determination in deproteinized aqueous humor, simplifying preparation of biol. samples for anal. for stability studies. The differential pulse voltammetric (DPV) method using boron doped diamond electrode (BDDE), based on characteristic oxidation peaks, is proposed and successfully applied. The linearity range was within 5.0 × 10^-6 to 5.0 × 10^-5 M of brimonidine, and limit of detection and limit of quantitation were 1.94 × 10^-6 M and 6.46 × 10^-6 M, resp. Intra-day and inter-day precision and accuracy were evaluated and all results were in accordance with validation ICH guidelines. The best short-term stability study results were obtained for a concentration level of 3.0 × 10^-5 M expressed by deviation of + 1.86% between initial and post storage concentrations A long-term stability study was performed for two concentrations of 3.0 × 10^-5 M and 5.0 × 10^-5 M and resulted in deviations of + 1.63% and + 3.56%, resp. A freeze and thaw stability study indicated that samples might be frozen only once. The enhancement of DPV/BDDE method sensitivity gained by modification, for the anal. of immeasurable BRIM quantities in native, untreated aqueous humor, was reached for quantities of 6 or 12 nmol/0.1 mL aqueous humor with acceptable accuracy (up to + 7.5%). The nature of the process-the irreversible one electron oxidation voltammetric peak of BRIM-limited the sensitivity. Only electrochem. pre-treatment of the BDD electrode before each measurement significantly speeded up the whole procedure. The advantages of the proposed method are simplicity, short-time performance, and good specificity/selectivity, as well as satisfactory accuracy, and no chem. modification of BDDE was necessary. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Related Products of 70359-46-5).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxaline derivatives are important constituents of pharmacologically active compounds, including antibacterial, antibiotic and antineoplastic, antifungal, anti-inflammatory and analgesic drugs. Quinoxalines are used as dyes, pharmaceuticals, and antibiotics such as echinomycin, levomycin exhibiting antitumoral properties. Quinoxalines establish also the basis of anthelmintics and receptor antagonists.Related Products of 70359-46-5

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Efficient circularly polarized photoluminescence and electroluminescence of chiral spiro-skeleton based thermally activated delayed fluorescence molecules was written by Zhang, Yi-Pin;Song, Shi-Quan;Mao, Meng-Xi;Li, Cheng-Hui;Zheng, You-Xuan;Zuo, Jing-Lin. And the article was included in Science China: Chemistry in 2022.SDS of cas: 105598-27-4 This article mentions the following:

Chiral thermally activated delayed fluorescence (TADF) mols. showing circularly polarized luminescence (CPL) have great potential in 3D displays. However, the relationships among CPL property, device performance and mol. structure are still not clear. In this article, we develop a strategy to promote dissymmetry factors without sacrifice in device performance and study the impact of mol. structures towards CPL property. Three novel TADF enantiomers are synthesized and studied. (R/S)-SCN with diminutive cyano group as an acceptor shows dissymmetry factor |g_PL| ∼ 1.4×10^-3 and noticeable organic light-emitting diode (OLED) performances with a maximum external quantum efficiency (EQE_max) of 23.0%. For (R/S)-SPHCN, the prolonged electron withdrawing group benzonitrile enhances |g_PL| up to 3.6×10^-3 with decreased device EQE_max of 15.4%. By further replacing benzonitrile with (trifluoromethyl)pyridine, the enantiomers of (R/S)-SCFPY show similar |g_PL| factors of 3.5×10^-3 and device EQE_max up to 23.3%, which represents the highest efficiency among sprio-type TADF materials based OLEDs. Furthermore, the OLEDs also show obvious circularly polarized electroluminescence with g_EL factors of -1.4/1.8×10^-3, -3.6/3.6 x10^-3 and -3.7/3.6×10^-3, resp. These results indecate by delicate functional group engineering, high g factor can be achieved while maintaining decent device performances. Besides, (R/S)-SCFPY represents an impressive TADF emitter, which shows promoted g factor and recorded high device EQE_max among similar mols. In the experiment, the researchers used many compounds, for example, Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile (cas: 105598-27-4SDS of cas: 105598-27-4).

Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile (cas: 105598-27-4) belongs to quinoxaline derivatives. Quinoxalines have received a significant amount of attention due to their potential use in fighting various pathophysiological conditions like epilepsy, Parkinson’s, and Alzheimer’s diseases. Quinoxalines are used as dyes, pharmaceuticals, and antibiotics such as echinomycin, levomycin exhibiting antitumoral properties. Quinoxalines establish also the basis of anthelmintics and receptor antagonists.SDS of cas: 105598-27-4

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

The effect of brimonidine and proparacaine on metabolic enzymes: Glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase was written by Caliskan, Buesra;Oeztuerk Kesebir, Arzu;Demir, Yeliz;Akyol Salman, Ilknur. And the article was included in Biotechnology and Applied Biochemistry in 2022.Synthetic Route of C15H16BrN5O6 This article mentions the following:

Oxidative stress is to upregulate the pentose phosphate pathway (PPP). The PPP consists of two functional branches, glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconaste dehydrogenase (6PGD). Glutathione reductase (GR) has a significant role in catalyzing an oxidized glutathione form into a reduced form. The purpose of this study is to investigate the effects of brimonidine and proparacaine on the activity of 6PGD, G6PD, and GR enzymes purified from human erythrocytes. Brimonidine displayed considerable inhibition profile against G6PD with IC50 value and KI constant of 29.93 ± 3.56 and 48.46 ± 0.66μM, resp. On the other hand, proparacaine had no inhibitory effect against G6PD. KI values were found to be 66.06 ± 0.78 and 811.50 ± 11.13μM for brimonidine and proparacaine, resp., for 6PGD. KI values were found to be 144.10 ± 2.01 and 1,654.00 ± 26.29μM for brimonidine and proparacaine, resp., for GR. Herein, also in silico mol. docking studies were performed between drugs and enzymes. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Synthetic Route of C15H16BrN5O6).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxaline is isomeric with other naphthyridines including quinazoline, phthalazine and cinnoline. Quinoxaline and its analogues may also be formed by reduction of amino acids substituted 1,5-difluoro-2,4-dinitrobenzene (DFDNB),One study used 2-iodoxybenzoic acid (IBX) as a catalyst in the reaction of benzil with 1,2-diaminobenzene.Synthetic Route of C15H16BrN5O6

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

[Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety]. was written by Kurysheva, N I. And the article was included in Vestnik oftalmologii in 2019.Category: quinoxaline This article mentions the following:

Glaucoma is the main cause of irreversible blindness in the world. Among the hypotensive eye drops, an important place belongs to the selective α2-adrenergic receptor antagonist brimonidine. This part of the review focuses on key pharmacological and therapeutic characteristics of brimonidine and its mode of action. The article also discusses the side effects of brimonidine and the methods of their prevention. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Category: quinoxaline).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. The antitumoral properties of quinoxaline compounds have been of interest. Recently, quinoxaline and its analogs have been investigated as the catalyst’s ligands.Category: quinoxaline

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Visible-light-induced decarboxylative alkylation of quinoxalin-2(1H)-ones with phenyliodine(III) dicarboxylates by cerium photocatalysis was written by Zhang, Lixi;He, Jingwen;Zhang, Pengfei;Zheng, Kai;Shen, Chao. And the article was included in Molecular Catalysis in 2022.Category: quinoxaline This article mentions the following:

3-Alkylquinoxalin-2(1H)-ones I [R¹ = H, 6-Me, 7-Cl, etc.; R² = Me, Et, Pr, propargyl, allyl, Bn; R³ = Me, Et, cyclopropyl, etc.] were prepered via visible-light-induced decarboxylative alkylation of quinoxalin-2(1H)-ones with phenyliodine(III) dicarboxylate using inexpensive CeCl₃ as photocatalyst. Novel protocol had advantages of mild conditions, high yields and good substrate scope. Control experiments indicated that radical mechanism was responsible for the present transformation. In the experiment, the researchers used many compounds, for example, 6-Bromoquinoxalin-2(1H)-one (cas: 55687-34-8Category: quinoxaline).

6-Bromoquinoxalin-2(1H)-one (cas: 55687-34-8) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. Quinoxaline-1,4-di-N-oxide derivatives have shown to improve the biological results and are endowed with anti-viral, anti-cancer, anti-bacterial, and anti-protozoal activities with application in many other therapeutic areas.Category: quinoxaline

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

A Novel Palladium-Catalyzed Synthesis of 1,2-Dihydroquinoxalines and 3,4-Dihydroquinoxalinones was written by Soederberg, Bjoern C. G.;Wallace, Jeffery M.;Tamariz, Joaquin. And the article was included in Organic Letters in 2002.Reference of 80636-30-2 This article mentions the following:

Reactions of enamines, derived from 2-nitroanilines and α-substituted aldehydes, with carbon monoxide (6 atm) in the presence of a catalytic amount of bis(dibenzylideneacetone)palladium(0) (Pd(dba)₂) and 1,3-bis(diphenylphosphino)propane (dppp) afford readily separated mixtures of 1,2-dihydroquinoxalines and 3,4-dihydroquinoxalinones. Addition of a catalytic amount of 1,10-phenanthroline to the reaction mixture substantially improved the yield of products. In the experiment, the researchers used many compounds, for example, 3,3-Dimethyl-3,4-dihydroquinoxalin-2(1H)-one (cas: 80636-30-2Reference of 80636-30-2).

3,3-Dimethyl-3,4-dihydroquinoxalin-2(1H)-one (cas: 80636-30-2) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. Quinoxaline-1,4-di-N-oxide derivatives have shown to improve the biological results and are endowed with anti-viral, anti-cancer, anti-bacterial, and anti-protozoal activities with application in many other therapeutic areas.Reference of 80636-30-2

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

A Promising Multifunctional Deep-Blue Fluorophor for High-Performance Monochromatic and Hybrid White OLEDs with Superior Efficiency/Color Stability and Low Efficiency Roll-Off was written by Ying, Shian;Liu, Wei;Peng, Ling;Dai, Yanfeng;Yang, Dezhi;Qiao, Xianfeng;Chen, Jiangshan;Wang, Lei;Ma, Dongge. And the article was included in Advanced Optical Materials in 2022.Recommanded Product: Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile This article mentions the following:

High-performance deep-blue fluorescent materials matching the required Commission Internationale de l′Eclairage y coordinate value (CIEy) of < 0.08 are much-needed in organic light-emitting diodes (OLEDs) for realizing the perfect application of full-color displays. However, deep-blue fluorophors commonly show unsatisfactory performance due to the intrinsic large bandgap characteristic. Here, the deep-blue nondoped OLED with the good CIE coordinates of (0.15, 0.07) and external quantum efficiency (EQE) of ≈9% is achieved based on a multifunctional and efficient anthracene-based fluorophor (2M-ph-3CzAnBzt). Using it as a host, the sky-blue fluorescent OLED realizes the maximum EQE of 9.50%, and keeps as high as 9.27% and 8.56% at 1000 and 5000 cd m^-2. More surprisingly, high-performance hybrid white OLEDs (WOLEDs) with good color stability and low roll-off are achieved by using it as the blue emitter. Two-color WOLED shows the forward-viewing efficiencies of 20.46%, and 76.80 lm W^-1. The three-color WOLED emitting a candlelight with the color rendering index of ≥ 82 realizes the maximum EQE of 21.49% and remains 20.80% at 1000 cd m^-2. Such superior electroluminescence performance achieved in these OLEDs ranks among the highest values based on deep-blue fluorophors with CIEy < 0.08. In the experiment, the researchers used many compounds, for example, Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile (cas: 105598-27-4Recommanded Product: Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile).

Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile (cas: 105598-27-4) belongs to quinoxaline derivatives. Compounds possessing quinoxaline derivatives were bestowed with a variety of significant biological properties such as antiviral, antimalarial, anticancer, DNA intercalation, DNA duplex stabilization, and many others. Quinoxalines are used as dyes, pharmaceuticals, and antibiotics such as echinomycin, levomycin exhibiting antitumoral properties. Quinoxalines establish also the basis of anthelmintics and receptor antagonists.Recommanded Product: Dipyrazino[2,3-f:2′,3′-h]quinoxaline-2,3,6,7,10,11-hexacarbonitrile

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury was written by Lou, Xiaotong;Hu, Yuanyuan;Zhang, Hong;Liu, Jia;Zhao, Yin. And the article was included in Journal of Nanobiotechnology in 2021.Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate This article mentions the following:

Oxidative stress contributes to retina ganglion cells (RGCs) loss in variety of ocular diseases, including ocular trauma, ocular vein occlusion, and glaucoma. Scavenging the excessed reactive oxygen species (ROS) in retinal neurovascular unit could be beneficial to RGCs survival. In this study, a polydopamine (PDA)-based nanoplatform is developed to protect RGCs. The PDA nanoparticles efficiently eliminate multi-types of ROS, protect endothelia and neuronal cells from oxidative damage, and inhibit microglia activation in retinas. In an optic nerve crush (ONC) model, single intravitreal injection of PDA nanoparticles could significantly attenuate RGCs loss via eliminating ROS in retinas, reducing the inflammatory response and maintaining barrier function of retinal vascular endothelia. Comparative transcriptome anal. of the retina implied that PDA nanoparticles improve RGCs survival probably by altering the expression of genes involved in inflammation and ROS production Importantly, as a versatile drug carrier, PDA nanoparticles could deliver brimonidine (a neuroprotection drug) to synergistically attenuate RGCs loss and promote axon regeneration, thus restore visual function. The PDA nanoparticle-based therapeutic nanoplatform displayed excellent performance in ROS elimination, providing a promising probability for treating retinal degeneration diseases. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Compounds possessing quinoxaline derivatives were bestowed with a variety of significant biological properties such as antiviral, antimalarial, anticancer, DNA intercalation, DNA duplex stabilization, and many others. Modifying quinoxaline structure it is possible to obtain a wide variety of biomedical applications, namely antimicrobial activities and chronic and metabolic diseases treatment.Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

AMPAkines Have Novel Analgesic Properties in Rat Models of Persistent Neuropathic and Inflammatory Pain was written by Le, Alexander M.;Lee, Michelle;Su, Chen;Zou, Anthony;Wang, Jing. And the article was included in Anesthesiology in 2014.Synthetic Route of C14H15N3O This article mentions the following:

Background: Novel analgesics that do not suppress the respiratory drive are urgently needed. Glutamate signaling through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors plays important roles in central pain circuits. AMPAkines augment AMPA receptor function and have been shown to stimulate the respiratory drive to oppose opioid-induced hypoventilation. However, their role in chronic pain states remains unknown. Methods: The authors studied AMPAkines (CX546 and CX516) in rat spared nerve injury (SNI) model of neuropathic pain and Complete Freund’s Adjuvant (CFA) model of inflammatory pain. They measured the effect of AMPAkines on mech. and cold allodynia. They also evaluated their effect on depressive symptoms of pain using the forced swim test, as time of immobility on this test has been used as a measure for behavioral despair, a feature of depression. Results: The authors found that CX546, compared with DMSO (DMSO) control, reduced both mech. and sensory allodynia in SNI (DMSO group, n = 9; CX546 group, n = 11) and CFA models (both DMSO and CX546 groups, n = 9). They found that CX546, compared with control, also reduced depressive symptoms of pain by decreasing immobility on the forced swim test in both SNI (both DMSO and CX546 groups, n = 8) and CFA models (both DMSO and CX546 groups, n = 10). Finally, they found that CX516, compared with control, also reduced mech. and cold allodynia in the SNI model (both DMSO and CX516 groups, n = 10). Conclusions: AMPAkines alleviate pain hypersensitivity as well as depression-like behavior associated with long-lasting nerve injury and inflammatory insult. In the experiment, the researchers used many compounds, for example, Piperidin-1-yl(quinoxalin-6-yl)methanone (cas: 154235-83-3Synthetic Route of C14H15N3O).

Piperidin-1-yl(quinoxalin-6-yl)methanone (cas: 154235-83-3) belongs to quinoxaline derivatives. Quinoxalines have received a significant amount of attention due to their potential use in fighting various pathophysiological conditions like epilepsy, Parkinson’s, and Alzheimer’s diseases. They are well-known for application in organic light emitting devices, polymers and pharmaceutical agents. The quinoxaline-containing polymers are applicable in optical devices due to their thermal stability and low band gap.Synthetic Route of C14H15N3O

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Effect of Topical Brimonidine on Alcohol-Induced Flushing in Asian Individuals: A Randomized Clinical Trial. was written by Yu, Wesley Y;Lu, Brian;Tan, Daniel;Aroyan, Christine;Shinkai, Kanade;Leslie, Kieron S;Fox, Lindy P;Yu, Siegrid;Neuhaus, Isaac M;Grekin, Roy C;Arron, Sarah T. And the article was included in JAMA dermatology in 2020.Synthetic Route of C15H16BrN5O6 This article mentions the following:

Importance: Alcohol flushing syndrome (AFS, also known as Asian glow and Asian flush) affects 20% to 47% of East Asians and causes significant psychosocial distress. There are no approved treatments for this condition. Objective: To determine whether brimonidine gel, 0.33%, decreases facial erythema in patients with AFS after consumption of alcohol. Design, Setting, and Participants: In this randomized clinical trial, 20 healthy volunteers of East Asian descent with a self-reported history of AFS were recruited between April 2018 and March 2019. Interventions: Participants were randomized to application of brimonidine gel to either the left or right half of their face. Placebo control was applied to the opposite side. After 30 minutes, participants ingested alcohol. Main Outcomes and Measures: Outcomes were specified before data collection. The difference in erythema between the treated and placebo side of each participant’s face was measured 60 minutes after drug application (primary outcome) and at 90 and 120 minutes after drug application (secondary outcomes). Participants were asked to rate their likelihood of using the medication again and their likelihood of recommending the medication to a friend on a scale of 0 to 10. Results: The mean (SD) age of the 20 individuals enrolled in the study was 30.5 (8.4) years, and there were 10 women (50%). There was a significant difference in erythema at 60 minutes after drug application as measured by the difference in Clinician Erythema Assessment score (2.1; 95% CI, 1.5-2.71; P < .001) and by the difference in Subject Self-Assessment score (1.7; 95% CI, 1.1- 2.3; P < .001). This effect persisted at 90 and 120 minutes. Individuals were likely to use the medication again (7.2; 95% CI, 6.0-8.3) and would also recommend it to a friend (7.6; 95% CI, 6.5-8.6). Conclusions and Relevance: This study demonstrates that brimonidine gel is effective in reducing the facial erythema of AFS. Patients with psychosocial distress due to AFS may benefit from treatment with brimonidine. Trial Registration: ClinicalTrials.gov identifier: NCT03497442. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Synthetic Route of C15H16BrN5O6).

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxalines are important class of heterocyclic compounds, associated with wider pharmacological applications. Quinoxaline and its analogues may also be formed by reduction of amino acids substituted 1,5-difluoro-2,4-dinitrobenzene (DFDNB),One study used 2-iodoxybenzoic acid (IBX) as a catalyst in the reaction of benzil with 1,2-diaminobenzene.Synthetic Route of C15H16BrN5O6

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider